Research analysts at Seaport Global Securities began coverage on shares of Innophos (NASDAQ:IPHS) in a report released on Thursday. The firm set a “buy” rating on the specialty chemicals company’s stock.
Several other equities analysts also recently commented on the company. BidaskClub raised Innophos from a “hold” rating to a “buy” rating in a research report on Thursday, February 7th. ValuEngine raised Innophos from a “strong sell” rating to a “sell” rating in a research report on Monday, February 4th. Finally, Zacks Investment Research raised Innophos from a “strong sell” rating to a “hold” rating in a research report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $51.00.
Innophos stock traded up $1.61 during mid-day trading on Thursday, hitting $33.39. The company’s stock had a trading volume of 640 shares, compared to its average volume of 101,427. The company has a market capitalization of $627.73 million, a PE ratio of 13.46 and a beta of 1.38. The company has a quick ratio of 1.36, a current ratio of 2.79 and a debt-to-equity ratio of 1.01. Innophos has a one year low of $22.57 and a one year high of $50.40.
Innophos (NASDAQ:IPHS) last announced its quarterly earnings data on Wednesday, February 20th. The specialty chemicals company reported $0.54 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.03. The company had revenue of $192.74 million for the quarter, compared to the consensus estimate of $189.60 million. Innophos had a return on equity of 13.30% and a net margin of 2.49%. Innophos’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.52 EPS. As a group, research analysts anticipate that Innophos will post 2.25 earnings per share for the current year.
Hedge funds have recently modified their holdings of the business. Bank of Montreal Can lifted its holdings in shares of Innophos by 79.8% in the 4th quarter. Bank of Montreal Can now owns 1,300 shares of the specialty chemicals company’s stock worth $32,000 after buying an additional 577 shares during the period. Public Employees Retirement System of Ohio lifted its holdings in shares of Innophos by 14.1% in the 4th quarter. Public Employees Retirement System of Ohio now owns 2,708 shares of the specialty chemicals company’s stock worth $66,000 after buying an additional 334 shares during the period. Quantamental Technologies LLC purchased a new stake in shares of Innophos in the 4th quarter worth $81,000. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Innophos by 353.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 6,403 shares of the specialty chemicals company’s stock worth $157,000 after buying an additional 4,991 shares during the period. Finally, Oregon Public Employees Retirement Fund purchased a new stake in shares of Innophos in the 4th quarter worth $183,000. Institutional investors and hedge funds own 88.30% of the company’s stock.
Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.
Featured Story: Investing in Dividend Stocks
Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.